Reference entry · Mitochondria-targeted tetrapeptide
SS-31
Also known as: Elamipretide · Bendavia · MTP-131
- Class
- Mitochondria-targeted tetrapeptide
- Primary targets (literature)
- Cardiolipin, inner mitochondrial membrane
- Regulatory context
- Investigational drug candidate (elamipretide). Catalog SS-31 is not pharmaceutical elamipretide without verified identity and regulatory context.
Overview
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide studied in mitochondrial dysfunction, heart failure, and rare disease research programs with published clinical-stage data — distinct from most catalog-only longevity peptides.
Mechanism in research literature
Literature describes selective accumulation at the inner mitochondrial membrane and interaction with cardiolipin, stabilizing electron transport and reducing oxidative stress markers in cell and animal models.
Common research focus areas
- Heart failure and mitochondrial myopathy trials
- Cardiolipin binding and ETC stabilization
- Clinical pharmacokinetics vs. catalog RUO supply
- Non-natural amino acid identity confirmation
Full literature roundup
Read the cited research summary
A mitochondria-targeted tetrapeptide studied in heart failure, mitochondrial myopathy, and rare disease trials. What elamipretide literature reports — and how catalog supply differs from clinical drug product.
SS-31 research roundup · 7 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.